SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [**REDACTED**] (assuming that the [**REDACTED**] is not exercised), the following persons will have interests or short positions in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, interested in 10% or more of the issued voting shares of any other member of our Group.

Shareholder	Nature of interest	Number of Shares interested in as of the Latest Practicable Date(1)	Approximate percentage of interest in our Company as of the Latest Practicable Date(1)	Number of Shares interested in immediately following the completion of the [REDACTED](1)	Approximate percentage of interest in our Company immediately following the completion of the [REDACTED](2)
			(%)		*(%)*
Dr. Zhou	Interest in controlled corporation; interest jointly held with another person	45,307,674 (L)(3)	38.76	[**REDACTED**] (L)(4)	[**REDACTED**]
Zeccogene	Beneficial owner	23,121,065 (L)	19.78	[**REDACTED**] (L)	[**REDACTED**]
Eccoforest	Beneficial owner	18,919,464 (L)	16.18	[**REDACTED**] (L)	[**REDACTED**]
Sinopharm Innovation(5)	Beneficial owner	8,104,697 (L)	6.93	[**REDACTED**] (L)	[**REDACTED**]
Infotech Ventures(5) . .	Interest in controlled corporation	8,104,697 (L)	6.93	[**REDACTED**] (L)	[**REDACTED**]
Shanghai Jianyi(5) . . .	Interest in controlled corporation	11,421,077 (L)	9.77	[**REDACTED**] (L)	[**REDACTED**]
CNPIC(5)	Interest in controlled corporation	11,421,077 (L)	9.77	[**REDACTED**] (L)	[**REDACTED**]
Shanghai Shenghui(5)	Interest in controlled corporation	11,421,077 (L)	9.77	[**REDACTED**] (L)	[**REDACTED**]
Mr. Wu Aimin (吳愛民)(6)	Interest in controlled corporation	11,447,607 (L)	9.79	[**REDACTED**] (L)	[**REDACTED**]

Notes:

(1) On the basis that the Preferred Shares will be converted into the Shares on a one-to-one basis by way of re-designation and re-classification immediately before the [**REDACTED**]. The letter "L" denotes the person's long position in the Shares.

(2) Based on the assumption that the [**REDACTED**] is not exercised.

(3) As of the Latest Practicable Date, both Zeccogene and Eccoforest are wholly owned by Dr. Zhou. As such, Dr. Zhou is deemed to be interested in the Shares held by Zeccogene and Eccoforest under the SFO.

Pursuant to an acting-in-concert agreement dated December 16, 2021 (the "**AIC Agreement**") entered into among Dr. Zhou, Zeccogene, Dr. Xu, and JFSE, Dr. Xu (including JFSE) (i) agreed to act in concert with Dr. Zhou (including Zeccogene) in relation to the exercise of their voting rights on matters in Shareholders' meeting of the Company; and (ii) acknowledged and confirmed that Dr. Zhou and Zeccogene's decision on such matters shall prevail. The AIC agreement shall be effective from the date of its execution and shall remain in force until the earlier of Dr. Xu or JFSE ceasing to be a Shareholder.

Yansun Holdings Limited ("**Yansun**") and Zeccogene entered into a voting proxy agreement dated December 16, 2021 (the "**Voting Proxy**"). Pursuant to the Voting Proxy, Yansun irrevocably and unconditionally appointed Zeccogene as its true and lawful attorney and proxy to vote the Shares held by Yansun or act for Yansun as its proxy, on all matters submitted to a vote at the Shareholders' meeting. The Voting Proxy shall be effective during the period commencing from the execution of such agreement and ending on the earliest of (i) the day that Yansun ceasing to hold any Shares or the day that Yansun transferred all the Shares it held; or (ii) the closing of any qualified [**REDACTED**] as stipulated under the effective Shareholders' agreement of the Company.

(4) Immediately following the completion of the [**REDACTED**], Eccoforest which holds unvested Shares is required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders' approval under the Listing Rules, unless otherwise required by law to vote in accordance with the beneficial owner's direction and such a direction is given. As such, Dr. Zhou will not be entitled to control the voting rights of Eccoforest upon the completion of the [**REDACTED**] and therefore is no longer deemed to be interested in the Shares held by Eccoforest.

(5) As of the Latest Practicable Date, Shanghai Sinopharm Innovation Equity Investment Fund Partnership (Limited Partnership) (上海國藥創新股權投資基金合夥企業(有限合夥)) ("**Sinopharm Innovation**") held 8,104,697 Series A Preferred Shares.

Sinopharm Innovation is a limited partnership established in the PRC and is managed by Shanghai Jianyi Chuangxin Private Equity Fund Management Co., Ltd. (上海健壹創信私募基金管理有限公司) ("**Jianyi Chuangxin**"). Jianyi Chuangxin is owned by Sinopharm Capital Management Co., Ltd. (上海健壹私募基金管理有限公司) ("**Shanghai Jianyi**") and Infotech Ventures Co., Ltd. (盈富泰克創業投資有限公司) ("**Infotech Ventures**") as to 35% and 35% of the equity interest, respectively. As such, each of Shanghai Jianyi and Infotech Ventures is interested in the Shares held by Sinopharm Innovation under the SFO.

As of the Latest Practicable Date, Sinopharm Zhongsheng (Shanghai) Biological Equity Investment Fund Partnership (Limited Partnership) (國藥中生(上海)生物股權投資基金合夥企業(有限合夥)) ("**Sinopharm Zhongsheng**") held 3,316,380 Series A-1 Preferred Shares. Sinopharm Zhongsheng is a limited partnership established in the PRC and is managed by Shanghai Jianyi. Shanghai Jianyi is owned by Shanghai Shenghui Investment Management Partnership (Limited Partnership) (上海聖匯投資管理合夥企業(有限合夥)) ("**Shanghai Shenghui**") and China National Pharmaceutical Investment Co., Ltd. (中國醫藥投資有限公司) ("**CNPIC**") CNPIC as to 65% and 35% of the equity interest, respectively. Shanghai Shenghui is owned by Mr. Wu Aimin (吳愛民) ("**Mr. Wu**") as to 95% of the equity interest. Therefore, each of Shanghai Jianyi, Shanghai Shenghui, CNPIC, and Mr. Wu is deemed to be interested in the Shares held in aggregate by Sinopharm Innovation and Sinopharm Zhongsheng under the SFO.

(6) As of the Latest Practicable Date, Shanghai Shengcheng Investment Management Partnership (Limited Partnership) (上海聖成投資管理合夥企業(有限合夥)) ("**Shanghai Shengcheng**") held 26,530 Series A-1 Preferred Shares. Shanghai Shengcheng is a limited partnership established in the PRC and is managed by its general partner, Mr. Wu, holding approximately 58.00% of the partnership interest. Therefore, Mr. Wu is deemed to be interested in the Shares held in aggregate by Sinopharm Innovation, Sinopharm Zhongsheng and Shanghai Shengcheng under the SFO.

Save as disclosed above, our Directors are not aware of any person who will, immediately following the completion of the [**REDACTED**] (assuming that the [**REDACTED**] is not exercised), have any interest and/or short position in the Shares or underlying Shares of our Company which will fall to be disclosed to our Company pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or who will be, directly or indirectly, interested in 10% or more of the issued voting shares of any other member of our Group.